• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析滤泡性淋巴瘤向弥漫性大 B 细胞淋巴瘤的转化。

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

机构信息

Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),Madrid, Spain.

出版信息

PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.

DOI:10.1371/journal.pone.0212813
PMID:30802265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6388933/
Abstract

Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation to a more aggressive subtype with poorer prognosis. This study aimed to improve our understanding of the genetics underlying FL histological transformation, and to identify genetic drivers or promoters of the transformation by elucidating the differences between FL samples from patients who did and did not transform. We conducted targeted massive parallel sequencing of 22 pre-transformed FL/transformed diffuse large B-cell lymphoma pairs and 20 diagnostic samples from non-transformed FL patients. Additionally, 22 matched samples from 11 transformed FL patients (pre-transformed FL and diffuse large B-cell lymphoma) and 9 non-transformed FLs were studied for copy number variation using SNP arrays. We identified recurrently mutated genes that were enriched at transformation, most notably LRP1B, GNA13 and POU2AF1, which have roles in B-cell differentiation, GC architecture and migration. Mutations in POU2AF1 might be associated with lower levels of expression, were more frequent in transformed FLs, and seemed to be specific to transformed- compared with de novo-diffuse large B-cell lymphomas. Pre-transformed FLs carried more mutations per sample and had greater subclonal heterogeneity than non-transformed FLs. Finally, we identified four mutated genes in FL samples that differed between patients who did and did not transform: NOTCH2, DTX1, UBE2A and HIST1H1E. The presence of mutations in these genes was associated with shorter time to transformation when mutated in the FL biopsies. This information might be useful for identifying patients at higher risk of transformation.

摘要

滤泡性淋巴瘤(FL)是一种惰性但基本上无法治愈的疾病。一些患者会发生组织学转化,转化为侵袭性更强、预后更差的亚型。本研究旨在深入了解 FL 组织学转化的遗传学基础,并通过阐明未转化和已转化的 FL 样本之间的差异,确定转化的遗传驱动因子或促进因子。我们对 22 对未经转化的 FL/转化弥漫性大 B 细胞淋巴瘤和 20 例非转化 FL 患者的诊断样本进行了靶向大规模平行测序。此外,对 11 例经转化的 FL 患者(未经转化的 FL 和弥漫性大 B 细胞淋巴瘤)的 22 个匹配样本和 9 例非转化 FL 的 SNP 芯片进行了拷贝数变异研究。我们鉴定了在转化过程中富集的高频突变基因,特别是 LRP1B、GNA13 和 POU2AF1,它们在 B 细胞分化、GC 结构和迁移中发挥作用。POU2AF1 中的突变可能与表达水平降低有关,在转化的 FL 中更为频繁,而且似乎是转化性弥漫性大 B 细胞淋巴瘤特有的,而不是新发弥漫性大 B 细胞淋巴瘤。与非转化的 FL 相比,未经转化的 FL 每个样本携带更多的突变,具有更大的亚克隆异质性。最后,我们在 FL 样本中发现了 4 个在未转化和已转化患者之间存在差异的突变基因:NOTCH2、DTX1、UBE2A 和 HIST1H1E。当这些基因在 FL 活检中发生突变时,存在突变与向转化的时间较短有关。这些信息可能有助于识别具有更高转化风险的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/4004112b7816/pone.0212813.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/717a7367808e/pone.0212813.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/873b55692296/pone.0212813.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/4004112b7816/pone.0212813.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/717a7367808e/pone.0212813.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/873b55692296/pone.0212813.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e2/6388933/4004112b7816/pone.0212813.g003.jpg

相似文献

1
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.解析滤泡性淋巴瘤向弥漫性大 B 细胞淋巴瘤的转化。
PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.
2
Transformed follicular lymphoma.转化型滤泡性淋巴瘤
Ann Hematol. 2018 Jan;97(1):17-29. doi: 10.1007/s00277-017-3151-2. Epub 2017 Oct 18.
3
Cell of origin of transformed follicular lymphoma.转化性滤泡性淋巴瘤的起源细胞。
Blood. 2015 Oct 29;126(18):2118-27. doi: 10.1182/blood-2015-06-649905. Epub 2015 Aug 25.
4
Transformation of indolent follicular lymphoma into diffuse large B-cell lymphoma - the molecular basis of "cancer aggressiveness".惰性滤泡性淋巴瘤向弥漫性大 B 细胞淋巴瘤的转化——“癌症侵袭性”的分子基础。
Klin Onkol. 2023 Fall;36(4):353-363. doi: 10.48095/ccko2023353.
5
Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.复发性非霍奇金淋巴瘤分子进展中MDM2和p53的频繁改变。
Histopathology. 2002 Oct;41(4):322-30. doi: 10.1046/j.1365-2559.2002.01506.x.
6
miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.在滤泡性淋巴瘤转化过程中,miR-31和miR-17-5p水平发生变化。
Hum Pathol. 2016 Apr;50:118-26. doi: 10.1016/j.humpath.2015.11.011. Epub 2015 Nov 30.
7
Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.生成并验证滤泡性淋巴瘤患者组织转化风险模型。
Mod Pathol. 2024 Jul;37(7):100516. doi: 10.1016/j.modpat.2024.100516. Epub 2024 May 17.
8
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.TP53突变在滤泡性淋巴瘤转化为弥漫性大B细胞淋巴瘤中作用有限。
Leukemia. 2005 Aug;19(8):1459-65. doi: 10.1038/sj.leu.2403802.
9
Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma.与滤泡性淋巴瘤转化为弥漫性大B细胞淋巴瘤相关的染色体拷贝数变化的鉴定。
Hum Pathol. 2003 Sep;34(9):915-23. doi: 10.1016/s0046-8177(03)00350-2.
10
Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes.滤泡性淋巴瘤向弥漫性大细胞淋巴瘤的转化:c-myc及其调控基因表达增加或减少的不同模式。
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8886-91. doi: 10.1073/pnas.132253599. Epub 2002 Jun 19.

引用本文的文献

1
Identification of IFI27 involvement in the progression of neuroblastoma through bioinformatics analysis and experimental assays.通过生物信息学分析和实验测定确定IFI27在神经母细胞瘤进展中的作用。
J Mol Histol. 2025 Feb 7;56(2):83. doi: 10.1007/s10735-024-10346-7.
2
Audit of B-cell cancer genes.B细胞癌基因的审计。
Blood Adv. 2025 Apr 22;9(8):2019-2031. doi: 10.1182/bloodadvances.2022009461.
3
Unraveling the complexity of follicular lymphoma: insights and innovations.解析滤泡性淋巴瘤的复杂性:见解与创新

本文引用的文献

1
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.弥漫性大 B 细胞淋巴瘤的分子亚型与不同的发病机制和预后相关。
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
2
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传学与发病机制
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
3
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Am J Cancer Res. 2024 Dec 15;14(12):5573-5597. doi: 10.62347/MFUG2190. eCollection 2024.
4
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.分子生物标志物在预测滤泡性淋巴瘤患者高级别转化和结局中的作用:一项全面的系统性综述。
Int J Mol Sci. 2024 Oct 17;25(20):11179. doi: 10.3390/ijms252011179.
5
GeneRaMeN enables integration, comparison, and meta-analysis of multiple ranked gene lists to identify consensus, unique, and correlated genes.GeneRaMeN 能够整合、比较和荟萃分析多个排名基因列表,以识别共识、独特和相关的基因。
Brief Bioinform. 2024 Jul 25;25(5). doi: 10.1093/bib/bbae452.
6
Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma.病例报告:一名伴有MYC和BCL2重排的TdT阳性高级别B细胞淋巴瘤患者在同时治疗滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤后的突变演变。
Discov Oncol. 2024 Apr 25;15(1):129. doi: 10.1007/s12672-024-00991-5.
7
Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression.非编码突变导致超级增强子重新靶向,导致 B 细胞淋巴瘤进展过程中蛋白质合成失调。
Nat Genet. 2023 Dec;55(12):2160-2174. doi: 10.1038/s41588-023-01561-1. Epub 2023 Dec 4.
8
The implication of next-generation sequencing in the diagnosis and clinical management of non-Hodgkin lymphomas.新一代测序在非霍奇金淋巴瘤诊断及临床管理中的意义。
Front Oncol. 2023 Nov 8;13:1275327. doi: 10.3389/fonc.2023.1275327. eCollection 2023.
9
A genetic profiling guideline to support diagnosis and clinical management of lymphomas.用于支持淋巴瘤诊断和临床管理的基因谱分析指南。
Clin Transl Oncol. 2024 May;26(5):1043-1062. doi: 10.1007/s12094-023-03307-1. Epub 2023 Sep 6.
10
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.滤泡性淋巴瘤进展相关突变预示着诊断时预后不良:Alliance A151303 研究。
Blood Adv. 2023 Sep 26;7(18):5524-5539. doi: 10.1182/bloodadvances.2023010779.
将弥漫性大 B 细胞淋巴瘤中的基因组改变进行整合,可鉴定出新的相关途径和潜在的治疗靶点。
Leukemia. 2018 Mar;32(3):675-684. doi: 10.1038/leu.2017.251. Epub 2017 Aug 14.
4
Can histologic transformation of follicular lymphoma be predicted and prevented?滤泡性淋巴瘤的组织学转化可以预测和预防吗?
Blood. 2017 Jul 20;130(3):258-266. doi: 10.1182/blood-2017-03-691345. Epub 2017 Apr 13.
5
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.BCL6拮抗NOTCH2以维持人滤泡性淋巴瘤细胞的存活。
Cancer Discov. 2017 May;7(5):506-521. doi: 10.1158/2159-8290.CD-16-1189. Epub 2017 Feb 23.
6
Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.Deltex-1突变预示弥漫性大B细胞淋巴瘤患者预后不良。
Haematologica. 2017 May;102(5):e195-e198. doi: 10.3324/haematol.2016.157495. Epub 2017 Feb 9.
7
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.复发性体细胞突变影响滤泡性淋巴瘤中的B细胞受体信号通路基因。
Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.
8
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.滤泡性淋巴瘤的组织学转化与进展:一项克隆进化研究
PLoS Med. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec.
9
Prognostic factors in follicular lymphoma: new tools to personalize risk.滤泡性淋巴瘤的预后因素:个性化风险评估的新工具
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):269-276. doi: 10.1182/asheducation-2016.1.269.
10
Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells.LRP1B的染色体、表观遗传和微小RNA介导的失活,LRP1B是甲状腺癌细胞外环境的调节因子。
Oncogene. 2017 Jan 5;36(1):146. doi: 10.1038/onc.2016.143. Epub 2016 Aug 8.